Press and Media

News, press releases, and media contact information

BINOSTO® (alendronate sodium) effervescent tablet for oral solution 70 mg is big news in osteoporosis therapy! Be aware of the latest—check back here to find postings of new press releases and important news about BINOSTO.


FDA approves BINOSTO®, First and Only Effervescent Osteoporosis Treatment in a Buffered Solution

Press releases

Mission and EffRx Bring New Osteoporosis Medication to the United States and Canada, April 17, 2012

Media Contact Information

For more information about BINOSTO or Mission Pharmacal, please contact:

Drew Deeter DEETER Strategic Public Relations 111 East Court Street Doylestown, PA 18901 215.348.3890 [email protected]

This content comes from a hidden element on this page.

The inline option preserves bound JavaScript events and changes, and it puts the content back where it came from when it is closed.

Click me, it will be preserved!

If you try to open a new ColorBox while it is already open, it will update itself with the new content.

Updating Content Example:
Click here to load new content